| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5683987 | SEMERGEN - Medicina de Familia | 2017 | 10 Pages |
Abstract
In this article an update is presented on the prevention and pharmacological treatment of the secondary pain from the virus infection. The most effective way to prevent post-herpetic neuralgia and its consequences is the prevention of herpes itself. A live attenuated vaccine (the Oka strain varicella zoster virus) has been available for several years, and is approved in adults aged 50 years old. Although this vaccine has shown to be effective against herpes zoster and post-herpetic neuralgia, its effectiveness decreases with age and is contraindicated in patients with some form of immunosuppression. Today the recombinant vaccines provide an alternative, and may be administered to immunocompromised persons.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
G. Calvo-Mosquera, A. González-Cal, D. Calvo-RodrÃguez, C.Y. Primucci, P. Plamenov-Dipchikov,